Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
Executive Summary
The narrowed indication granted for Forest Laboratories Inc.'s newly approved chronic obstructive pulmonary disease drug Daliresp (roflumilast) means that a quarter of all diagnosed COPD patients, or three million people, will be eligible for treatment, the firm said.
You may also be interested in...
NICE Stuns Merck With Demand For Additional Daxas Trial
NICE says it wants Merck to carry out an additional clinical trial of Daxas in conjunction with triple therapy for COPD, if the company is to get its drug into the NHS.
Human Genome Sciences Dodges Mortality Boxed Warning, REMS For Benlysta
Human Genome Sciences escaped a boxed label warning and a Risk Evaluation and Mitigation Strategy for its lupus drug Benlysta (belimumab), despite FDA expectations late in the review process that both would be needed.
Human Genome Sciences Dodges Mortality Boxed Warning, REMS For Benlysta
Human Genome Sciences escaped a boxed label warning and a Risk Evaluation and Mitigation Strategy for its lupus drug Benlysta (belimumab), despite FDA expectations late in the review process that both would be needed.